Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Boosted by Duquesne Family Office LLC

Duquesne Family Office LLC raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 530.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,997,400 shares of the company's stock after purchasing an additional 7,569,450 shares during the period. Teva Pharmaceutical Industries accounts for about 5.3% of Duquesne Family Office LLC's portfolio, making the stock its 4th biggest position. Duquesne Family Office LLC owned about 0.79% of Teva Pharmaceutical Industries worth $198,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $58,243,000. Marshall Wace LLP boosted its position in shares of Teva Pharmaceutical Industries by 87.8% in the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after purchasing an additional 2,410,420 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Teva Pharmaceutical Industries by 69.0% in the 4th quarter. Northern Trust Corp now owns 5,206,360 shares of the company's stock worth $114,748,000 after purchasing an additional 2,125,266 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $24.43.

Teva Pharmaceutical Industries Stock Up 5.5%

Shares of Teva Pharmaceutical Industries stock traded up $0.93 during trading hours on Monday, reaching $17.86. 11,636,663 shares of the company were exchanged, compared to its average volume of 10,036,212. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The stock's fifty day moving average is $15.18 and its 200 day moving average is $17.44. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a market cap of $20.24 billion, a PE ratio of -12.32, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same period last year, the firm earned $0.48 earnings per share. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% on a year-over-year basis. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.